Ovid Therapeutics Inc. (OVID): Price and Financial Metrics


Ovid Therapeutics Inc. (OVID): $3.35

0.05 (+1.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OVID to Watchlist
Sign Up

Industry: Biotech


Ranked

of 474

in industry

OVID POWR Grades


  • Value is the dimension where OVID ranks best; there it ranks ahead of 99.91% of US stocks.
  • OVID's strongest trending metric is Value; it's been moving up over the last 52 weeks.
  • OVID ranks lowest in Momentum; there it ranks in the 8th percentile.

OVID Stock Summary

  • With a price/earnings ratio of 1.77, Ovid Therapeutics Inc P/E ratio is greater than that of about just 0.59% of stocks in our set with positive earnings.
  • For OVID, its debt to operating expenses ratio is greater than that reported by only 0.33% of US equities we're observing.
  • As for revenue growth, note that OVID's revenue has grown 2,996.4% over the past 12 months; that beats the revenue growth of 99.62% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Ovid Therapeutics Inc, a group of peers worth examining would be RYTM, ETON, SGBX, EVFM, and IMH.
  • Visit OVID's SEC page to see the company's official filings. To visit the company's web site, go to www.ovidrx.com.

OVID Valuation Summary

  • OVID's EV/EBIT ratio is 0.2; this is 99.32% lower than that of the median Healthcare stock.
  • OVID's price/sales ratio has moved NA NA over the prior 53 months.
  • Over the past 53 months, OVID's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for OVID.

Stock Date P/S P/B P/E EV/EBIT
OVID 2021-08-31 1.1 1.2 2.0 0.2
OVID 2021-08-30 1.1 1.2 2.0 0.2
OVID 2021-08-27 1.1 1.2 2.0 0.2
OVID 2021-08-26 1.1 1.1 1.9 0.2
OVID 2021-08-25 1.1 1.2 2.0 0.3
OVID 2021-08-24 1.1 1.2 2.0 0.3

OVID's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OVID has a Quality Grade of C, ranking ahead of 59.21% of graded US stocks.
  • OVID's asset turnover comes in at 1.419 -- ranking 13th of 682 Pharmaceutical Products stocks.
  • QURE, ACER, and SCYX are the stocks whose asset turnover ratios are most correlated with OVID.

The table below shows OVID's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.419 1 -10.143
2021-03-31 1.963 1 -8.584
2020-12-31 0.184 1 18.535
2020-09-30 0.099 1 -10.445
2020-06-30 0.000 NA -8.770
2020-03-31 0.000 NA -6.119

OVID Price Target

For more insight on analysts targets of OVID, see our OVID price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.75 Average Broker Recommendation 1.5 (Moderate Buy)

OVID Stock Price Chart Interactive Chart >

Price chart for OVID

OVID Price/Volume Stats

Current price $3.35 52-week high $4.80
Prev. close $3.30 52-week low $2.25
Day low $3.24 Volume 127,300
Day high $3.35 Avg. volume 1,490,731
50-day MA $3.50 Dividend yield N/A
200-day MA $3.74 Market Cap 228.11M

Ovid Therapeutics Inc. (OVID) Company Bio


Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was founded in 2014 and is based in New York City, New York.


OVID Latest News Stream


Event/Time News Detail
Loading, please wait...

OVID Latest Social Stream


Loading social stream, please wait...

View Full OVID Social Stream

Latest OVID News From Around the Web

Below are the latest news stories about Ovid Therapeutics Inc that investors may wish to consider to help them evaluate OVID as an investment opportunity.

Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results

Ovid is implementing its business development program which intends to secure a series of opportunities that complement and enhance its pipeline of precision and small-molecule CNS medicinesA development program for soticlestat, which Ovid licensed to Takeda, has begun enrolling patients in two pivotal, Phase 3 trials for Lennox-Gastaut and Dravet syndromesCompany ended the third quarter of 2021 with cash and cash equivalents of $201.8 million NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ovid The

Yahoo | November 10, 2021

Ovid Therapeutics (NASDAQ:OVID) investors are sitting on a loss of 34% if they invested three years ago

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Yahoo | November 5, 2021

ProShare Advisors LLC Sells 9,306 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID)

ProShare Advisors LLC decreased its position in Ovid Therapeutics Inc. (NASDAQ:OVID) by 43.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,183 shares of the companys stock after selling 9,306 shares during the quarter. ProShare Advisors LLCs holdings in Ovid Therapeutics []

Dakota Financial News | October 30, 2021

Deutsche Bank AG Purchases 53,514 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID)

Deutsche Bank AG boosted its stake in shares of Ovid Therapeutics Inc. (NASDAQ:OVID) by 167.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 85,566 shares of the companys stock after purchasing an additional 53,514 shares during the period. Deutsche Bank AGs holdings in Ovid []

Dakota Financial News | October 28, 2021

16,200 Shares in Ovid Therapeutics Inc. (NASDAQ:OVID) Acquired by Jump Financial LLC

Jump Financial LLC bought a new position in shares of Ovid Therapeutics Inc. (NASDAQ:OVID) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 16,200 shares of the companys stock, valued at approximately $63,000. A number of other hedge funds and other institutional investors have also recently []

Dakota Financial News | October 24, 2021

Read More 'OVID' Stories Here

OVID Price Returns

1-mo -2.90%
3-mo -6.42%
6-mo -23.52%
1-year 0.75%
3-year 66.25%
5-year N/A
YTD 45.02%
2020 11.33%
2019 71.49%
2018 -75.48%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8891 seconds.